BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Farrell RJ, Alsahli M, Jeen Y, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial. Gastroenterology 2003;124:917-24. [DOI: 10.1053/gast.2003.50145] [Cited by in Crossref: 401] [Cited by in F6Publishing: 345] [Article Influence: 21.1] [Reference Citation Analysis]
Number Citing Articles
1 Nagase K, Fukunaga K, Kashiwamura S, Kono T, Kamikozuru K, Yokoyama Y, Hida N, Ohda Y, Takeda N, Yoshida K, Iimuro M, Kikuyama R, Kato K, Miwa H, Matsumoto T. Immunoregulatory Effects of Adsorptive Granulocyte and Monocyte Apheresis in Patients with Drug Refractory Crohn's Disease: Immunoregulatory Effects of GMA in CD. Therapeutic Apheresis and Dialysis 2011;15:367-73. [DOI: 10.1111/j.1744-9987.2011.00970.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
2 Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009;137:1628-1640. [PMID: 19664627 DOI: 10.1053/j.gastro.2009.07.062] [Cited by in Crossref: 361] [Cited by in F6Publishing: 331] [Article Influence: 27.8] [Reference Citation Analysis]
3 De Simone C, Amerio P, Amoruso G, Bardazzi F, Campanati A, Conti A, Gisondi P, Gualdi G, Guarneri C, Leoni L, Loconsole F, Mazzotta A, Musumeci ML, Piaserico S, Potenza C, Prestinari F. Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue? Expert Opin Biol Ther 2013;13:1673-82. [PMID: 24107126 DOI: 10.1517/14712598.2013.848194] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
4 Bermejo F, San Román AL, Algaba A, Van Domselaar M, Carneros JA, Rivero M, Piqueras B, Paz Valer M. Eficacia de la premedicación con un esteroide y un antihistamínico en la prevención de reacciones infusionales por infliximab. Gastroenterología y Hepatología 2008;31:629-32. [DOI: 10.1016/s0210-5705(08)75809-6] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
5 Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854 [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
6 Ito H. Novel therapy for Crohn’s disease targeting IL-6 signalling. Expert Opinion on Therapeutic Targets 2005;8:287-94. [DOI: 10.1517/14728222.8.4.287] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
7 Berns M, Hommes DW. Anti-TNF-α therapies for the treatment of Crohn’s disease: the past, present and future. Expert Opinion on Investigational Drugs 2016;25:129-43. [DOI: 10.1517/13543784.2016.1126247] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
8 Zabana Y, Domènech E, Mañosa M, Garcia-Planella E, Bernal I, Cabré E, Gassull MA. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ther 2010;31:553-60. [PMID: 20002026 DOI: 10.1111/j.1365-2036.2009.04206.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
9 Siddiqui MAA, Scott LJ. Infliximab: A Review of its Use in Crohn???s Disease and Rheumatoid Arthritis. Drugs 2005;65:2179-208. [DOI: 10.2165/00003495-200565150-00014] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 3.6] [Reference Citation Analysis]
10 Gecse KB, Végh Z, Lakatos PL. Optimizing biological therapy in Crohn’s disease. Expert Review of Gastroenterology & Hepatology 2015;10:37-45. [DOI: 10.1586/17474124.2016.1096198] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
11 Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clin Immunol 2013;149:534-55. [PMID: 24263283 DOI: 10.1016/j.clim.2013.09.006] [Cited by in Crossref: 166] [Cited by in F6Publishing: 147] [Article Influence: 18.4] [Reference Citation Analysis]
12 Friedman S. General principles of medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am. 2004;33:191-208, viii. [PMID: 15177534 DOI: 10.1016/j.gtc.2004.02.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
13 Joosse ME, Samsom JN, van der Woude CJ, Escher JC, van Gelder T. The Role of Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Alpha Agents in Children and Adolescents with Inflammatory Bowel Disease. Inflamm Bowel Dis 2015;21:2214-21. [PMID: 26284297 DOI: 10.1097/MIB.0000000000000420] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
14 Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2). Journal of the American Academy of Dermatology 2007;56:e55-79. [DOI: 10.1016/j.jaad.2006.07.019] [Cited by in Crossref: 77] [Cited by in F6Publishing: 59] [Article Influence: 5.1] [Reference Citation Analysis]
15 Shukla R, Vender RB. Pharmacology of TNF inhibitors. In: Weinberg JM, Buchholz R, editors. TNF-alpha Inhibitors. Basel: Birkhäuser-Verlag; 2006. pp. 23-44. [DOI: 10.1007/3-7643-7438-1_3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Afif W, Loftus EV, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133-1139. [PMID: 20145610 DOI: 10.1038/ajg.2010.9] [Cited by in Crossref: 356] [Cited by in F6Publishing: 332] [Article Influence: 29.7] [Reference Citation Analysis]
17 Dhillon S, Loftus EV. Medical Therapy of Crohn's Disease. Curr Treat Options Gastroenterol 2005;8:19-30. [PMID: 15625031 DOI: 10.1007/s11938-005-0048-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
18 Puig L, Sáez E, Lozano M, Bordas X, Carrascosa J, Gallardo F, Luelmo J, Sánchez-regaña M, Alsina M, García-patos V. Reacciones a la infusión de infliximab en pacientes dermatológicos. Actas Dermo-Sifiliográficas 2009;100:103-12. [DOI: 10.1016/s0001-7310(09)70227-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
19 Lobatón T, Vermeire S, Van Assche G, Rutgeerts P. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:579-594. [PMID: 24479980 DOI: 10.1111/apt.12639] [Cited by in Crossref: 125] [Cited by in F6Publishing: 115] [Article Influence: 15.6] [Reference Citation Analysis]
20 Di Sabatino A, Rovedatti L, Vidali F, Macdonald TT, Corazza GR. Recent advances in understanding Crohn’s disease. Intern Emerg Med. 2013;8:101-113. [PMID: 21553239 DOI: 10.1007/s11739-011-0599-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
21 Bhatia JK, Korelitz BI, Panagopoulos G, Lobel E, Mirsky F, Sultan K, DiSanti W, Chun A, Keenan G, Mamun K. A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn's disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone. J Clin Gastroenterol 2007;41:677-81. [PMID: 17667052 DOI: 10.1097/MCG.0b013e31802c2a23] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
22 Georgescu MT, Moorehead PC, van Velzen AS, Nesbitt K, Reipert BM, Steinitz KN, Schuster M, Hough C, Lillicrap D. Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms. Haematologica 2018;103:1403-13. [PMID: 29674503 DOI: 10.3324/haematol.2018.189852] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
23 Rudolph SJ, Weinberg DI, Mccabe RP. Long-Term Durability of Crohn’s Disease Treatment with Infliximab. Dig Dis Sci 2008;53:1033-41. [DOI: 10.1007/s10620-007-9969-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
24 Wang SL, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P, Lockton S, Ling N, Singh S. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods. 2012;382:177-188. [PMID: 22691619 DOI: 10.1016/j.jim.2012.06.002] [Cited by in Crossref: 148] [Cited by in F6Publishing: 137] [Article Influence: 14.8] [Reference Citation Analysis]
25 Scott FI, Lichtenstein GR. Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017. Curr Treat Options Gastroenterol 2018;16:147-64. [PMID: 29492747 DOI: 10.1007/s11938-018-0177-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
26 Hamzaoglu H, Cooper J, Alsahli M, Falchuk KR, Peppercorn MA, Farrell RJ. Safety of infliximab in Crohn's disease: a large single-center experience. Inflamm Bowel Dis. 2010;16:2109-2116. [PMID: 20848473 DOI: 10.1002/ibd.21290] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
27 Bratcher JM, Korelitz BI. Toxicity of infliximab in the course of treatment of Crohn's disease. Expert Opin Drug Saf 2006;5:9-16. [PMID: 16370952 DOI: 10.1517/14740338.5.1.9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
28 Rutgeerts P, van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126:1593-610. [DOI: 10.1053/j.gastro.2004.02.070] [Cited by in Crossref: 290] [Cited by in F6Publishing: 256] [Article Influence: 16.1] [Reference Citation Analysis]
29 Hindryckx P, Novak G, Vande Casteele N, Khanna R, Laukens D, Jairath V, Feagan BG. Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview. Drugs 2017;77:363-77. [PMID: 28233275 DOI: 10.1007/s40265-017-0693-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
30 Miheller P, Kiss LS, Lorinczy K, Lakatos PL. Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use? Expert Opinion on Biological Therapy 2012;12:179-92. [DOI: 10.1517/14712598.2012.644271] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
31 Poggioli G, Laureti S, Campieri M, Pierangeli F, Gionchetti P, Ugolini F, Gentilini L, Bazzi P, Rizzello F, Coscia M. Infliximab in the treatment of Crohn's disease. Ther Clin Risk Manag 2007;3:301-8. [PMID: 18360638 DOI: 10.2147/tcrm.2007.3.2.301] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
32 Aubin F, Carbonnel F, Wendling D. The complexity of adverse side-effects to biological agents. Journal of Crohn's and Colitis 2013;7:257-62. [DOI: 10.1016/j.crohns.2012.06.024] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
33 Din S, Dahele A, Fennel J, Aitken S, Shand AG, Arnott ID, Satsangi J. Use of methotrexate in refractory Crohn's disease: the Edinburgh experience. Inflamm Bowel Dis 2008;14:756-62. [PMID: 18275071 DOI: 10.1002/ibd.20405] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
34 Chaparro M, Andreu M, Barreiro-de Acosta M, García-Planella E, Ricart E, Domènech E, Esteve M, Merino O, Nos P, Peñalva M, Gisbert JP. Effectiveness of infliximab after adalimumab failure in Crohn's disease. World J Gastroenterol 2012; 18(37): 5219-5224 [PMID: 23066316 DOI: 10.3748/wjg.v18.i37.5219] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
35 Scott FI, Lichtenstein GR. Advances in Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease: 2015 in Review. Curr Treat Options Gastroenterol 2016;14:91-102. [PMID: 26847358 DOI: 10.1007/s11938-016-0085-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
36 Mrowietz U, de Jong EM, Kragballe K, Langley R, Nast A, Puig L, Reich K, Schmitt J, Warren RB. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2014;28:438-53. [PMID: 23437792 DOI: 10.1111/jdv.12118] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 8.7] [Reference Citation Analysis]
37 Fréling E, Peyrin-biroulet L, Poreaux C, Morali A, Waton J, Schmutz J, Guéant J, Barbaud A. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment. European Journal of Gastroenterology & Hepatology 2015;27:1200-8. [DOI: 10.1097/meg.0000000000000436] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 1.9] [Reference Citation Analysis]
38 Gorovits B, Baltrukonis DJ, Bhattacharya I, Birchler MA, Finco D, Sikkema D, Vincent MS, Lula S, Marshall L, Hickling TP. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clin Exp Immunol 2018;192:348-65. [PMID: 29431871 DOI: 10.1111/cei.13112] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
39 Bolia R, Rosenbaum J, Schildkraut V, Hardikar W, Oliver M, Cameron D, Alex G. Secondary Loss of Response to Infliximab in Pediatric Crohn Disease: Does It Matter How and When We Start? Journal of Pediatric Gastroenterology & Nutrition 2018;66:637-40. [DOI: 10.1097/mpg.0000000000001742] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Sehgal VN, Pandhi D, Khurana A. Biologics in dermatology: adverse effects. Int J Dermatol 2015;54:1442-60. [PMID: 26147909 DOI: 10.1111/ijd.12802] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
41 Nobile S, Gionchetti P, Rizzello F, Calabrese C, Campieri M. Mucosal healing in pediatric Crohn’s disease after anti-TNF therapy: a long-term experience at a single center. European Journal of Gastroenterology & Hepatology 2014;26:458-65. [DOI: 10.1097/meg.0000000000000045] [Cited by in Crossref: 24] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
42 Sohi S, Cohen RD. Management of refractory ulcerative colitis. Curr Treat Options Gastro 2006;9:234-45. [DOI: 10.1007/s11938-006-0042-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
43 Ghosh S. Maintenance therapy versus episodic therapy with infliximab for Crohn's disease. Nat Rev Gastroenterol Hepatol 2004;1:80-1. [DOI: 10.1038/ncpgasthep0039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
44 Kaplan G, Panaccione R. Use of combination therapy in IBD. Inflamm Bowel Dis 2008;14 Suppl 2:S219-21. [PMID: 18816768 DOI: 10.1002/ibd.20688] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
45 Comerford LW, Bickston SJ. Treatment of luminal and fistulizing Crohn's disease with infliximab. Gastroenterol Clin North Am. 2004;33:387-406, xi. [PMID: 15177545 DOI: 10.1016/j.gtc.2004.02.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
46 Travassos WJ, Cheifetz AS. Infliximab: Use in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2005;8:187-196. [PMID: 15913508 DOI: 10.1007/s11938-005-0011-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
47 Ghosh S. Management of Crohn’s disease from efficacy, quality of life and health economic perspectives. Expert Review of Pharmacoeconomics & Outcomes Research 2014;3:587-98. [DOI: 10.1586/14737167.3.5.587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
48 Feagan BG, Sandborn WJ, Lichtenstein G, Radford-smith G, Patel J, Innes A. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006;23:617-28. [DOI: 10.1111/j.1365-2036.2006.02791.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
49 Campi P, Benucci M, Manfredi M, Demoly P. Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. Curr Opin Allergy Clin Immunol 2007;7:393-403. [PMID: 17873578 DOI: 10.1097/ACI.0b013e3282ef96df] [Cited by in Crossref: 34] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
50 Guerra I, Bermejo F. Management of inflammatory bowel disease in poor responders to infliximab. Clin Exp Gastroenterol 2014;7:359-67. [PMID: 25258548 DOI: 10.2147/CEG.S45297] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
51 Wynands J, Belbouab R, Candon S, Talbotec C, Mougenot J, Chatenoud L, Schmitz J, Cézard J, Goulet O, Hugot J, Ruemmele FM. 12-Month Follow-up After Successful Infliximab Therapy in Pediatric Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 2008;46:293-8. [DOI: 10.1097/mpg.0b013e31815604cd] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
52 Zeng-Wang YM, Cares K, Thomas R, El-Baba M. The Effectiveness of Methylprednisolone as a Premedication Among the Pediatric Population for Preventing Infusion-Related Reactions to Infliximab. Gastroenterol Nurs 2021;44:449-54. [PMID: 34690297 DOI: 10.1097/SGA.0000000000000592] [Reference Citation Analysis]
53 Ono K, Nimura S, Hideshima Y, Nabeshima K, Nakashima M. Orally administered sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice. Exp Ther Med 2017;14:5485-90. [PMID: 29285080 DOI: 10.3892/etm.2017.5251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
54 Sartor R. Episodic retreatment versus scheduled maintenance therapy of Crohn’s disease with infliximab: Not so far apart. Gastroenterology 2004;126:598-601. [DOI: 10.1053/j.gastro.2003.12.019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
55 Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4:221-256. [PMID: 21122513 DOI: 10.1016/j.crohns.2009.12.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
56 Domènech E, Hinojosa J, Nos P, Garcia-Planella E, Cabré E, Bernal I, Gassull MA. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Aliment Pharmacol Ther 2005;22:1107-13. [PMID: 16305724 DOI: 10.1111/j.1365-2036.2005.02670.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 4.1] [Reference Citation Analysis]
57 Lin KK, Velayos F, Fisher E, Terdiman JP. Durability of infliximab dose intensification in Crohn's disease. Dig Dis Sci 2012;57:1013-9. [PMID: 22089254 DOI: 10.1007/s10620-011-1969-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
58 Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019;17:1655-1668.e3. [PMID: 30928454 DOI: 10.1016/j.cgh.2019.03.037] [Cited by in Crossref: 87] [Cited by in F6Publishing: 65] [Article Influence: 29.0] [Reference Citation Analysis]
59 Freeman K, Connock M, Auguste P, Taylor-Phillips S, Mistry H, Shyangdan D, Court R, Arasaradnam R, Sutcliffe P, Clarke A. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling. Health Technol Assess 2016;20:1-288. [PMID: 27845027 DOI: 10.3310/hta20830] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
60 Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14(3): 354-377 [PMID: 18200659 DOI: 10.3748/wjg.14.354] [Cited by in CrossRef: 137] [Cited by in F6Publishing: 128] [Article Influence: 9.8] [Reference Citation Analysis]
61 Khanna R, Sattin BD, Afif W, Benchimol EI, Bernard EJ, Bitton A, Bressler B, Fedorak RN, Ghosh S, Greenberg GR, Marshall JK, Panaccione R, Seidman EG, Silverberg MS, Steinhart AH, Sy R, Van Assche G, Walters TD, Sandborn WJ, Feagan BG. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther 2013;38:447-59. [PMID: 23848220 DOI: 10.1111/apt.12407] [Cited by in Crossref: 79] [Cited by in F6Publishing: 76] [Article Influence: 8.8] [Reference Citation Analysis]
62 Fefferman DS, Farrell RJ. Immunogenicity of biological agents in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:497-503. [PMID: 15867590 DOI: 10.1097/01.mib.0000161536.97412.41] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
63 McConnell J, Parvulescu-Codrea S, Behm B, Hill B, Dunkle E, Finke K, Snyder K, Tuskey A, Cox D, Woodward B. Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness. World J Gastrointest Pharmacol Ther 2012; 3(5): 74-82 [PMID: 23515325 DOI: 10.4292/wjgpt.v3.i5.74] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
64 Ran Z, Wu K, Matsuoka K, Jeen YT, Wei SC, Ahuja V, Chen M, Hu PJ, Andoh A, Kim HJ, Yang SK, Watanabe M, Ng SC, Hibi T, Hilmi IN, Suzuki Y, Han DS, Leung WK, Sollano J, Ooi CJ, Qian J. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. J Gastroenterol Hepatol 2021;36:637-45. [PMID: 32672839 DOI: 10.1111/jgh.15185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfá E. Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2010;38:82-9. [PMID: 19565360 DOI: 10.1007/s12016-009-8140-3] [Cited by in Crossref: 125] [Cited by in F6Publishing: 101] [Article Influence: 10.4] [Reference Citation Analysis]
66 Chen L, Xu CJ, Wu W, Ding BJ, Liu ZJ. Anti-TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta-analysis. J Dig Dis 2021;22:408-18. [PMID: 34048629 DOI: 10.1111/1751-2980.13026] [Reference Citation Analysis]
67 Ma C, Huang V, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study. Journal of Crohn's and Colitis 2014;8:1454-63. [DOI: 10.1016/j.crohns.2014.05.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
68 Baert F, Vermeire S, Gils A. Reply: To PMID 24486408. Clin Gastroenterol Hepatol 2015;13:1705-6. [PMID: 26107297 DOI: 10.1016/j.cgh.2015.06.015] [Reference Citation Analysis]
69 Felice C, Marzo M, Pugliese D, Papa A, Rapaccini GL, Guidi L, Armuzzi A. Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases. Expert Opinion on Biological Therapy 2015;15:1107-17. [DOI: 10.1517/14712598.2015.1044434] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
70 Hayes MJ, Stein AC, Sakuraba A. Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis: Combination therapy for ulcerative colitis. J Gastroenterol Hepatol 2014;29:1177-85. [DOI: 10.1111/jgh.12517] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
71 El-Matary W, Dykes DMH, Bauman L, Elkadri A, Carroll MW, Izaguirre MR, deBruyn J, Samson CM, Crim AM, Ali S, Grossman A. Rapid Infliximab Infusion in Children with Inflammatory Bowel Disease: A Multicenter North American Experience. Inflamm Bowel Dis 2017;23:2104-8. [PMID: 29140940 DOI: 10.1097/MIB.0000000000001259] [Cited by in Crossref: 10] [Article Influence: 2.5] [Reference Citation Analysis]
72 Hoshino M, Yoshio T, Onishi S, Minota S. Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis. Modern Rheumatology 2014;22:532-40. [DOI: 10.3109/s10165-011-0567-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
73 Courbette O, Aupiais C, Viala J, Hugot JP, Louveau B, Chatenoud L, Bourrat E, Martinez-Vinson C. Infliximab Paradoxical Psoriasis in a Cohort of Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019;69:189-93. [PMID: 30921262 DOI: 10.1097/MPG.0000000000002349] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
74 Seow CH, de Silva S, Kaplan GG, Devlin SM, Ghosh S, Panaccione R. Managing the risks of IBD therapy. Curr Gastroenterol Rep 2009;11:509-17. [PMID: 19903428 DOI: 10.1007/s11894-009-0077-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
75 Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The Benefit/Risk Profile of TNF-Blocking Agents: Findings of a Consensus Panel. Seminars in Arthritis and Rheumatism 2005;34:819-36. [DOI: 10.1016/j.semarthrit.2004.11.006] [Cited by in Crossref: 140] [Cited by in F6Publishing: 118] [Article Influence: 8.2] [Reference Citation Analysis]
76 Hanauer SB. Heading back to the trough (levels of biologics in IBD). Clin Gastroenterol Hepatol. 2015;13:548-551. [PMID: 25311382 DOI: 10.1016/j.cgh.2014.10.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
77 van Assche G, Vermeire S, Rutgeerts P. Emerging Biological Treatments in Inflammatory Bowel Diseases. Dig Dis 2006;24:131-6. [DOI: 10.1159/000090316] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
78 Mayer L, Young Y. Infusion reactions and their management. Gastroenterol Clin North Am 2006;35:857-66. [PMID: 17129817 DOI: 10.1016/j.gtc.2006.09.006] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
79 Papa A, Mocci G, Bonizzi M, Felice C, Andrisani G, Papa G, Gasbarrini A. Biological therapies for inflammatory bowel disease: controversies and future options. Expert Rev Clin Pharmacol. 2009;2:391-403. [PMID: 22112183 DOI: 10.1586/ecp.09.12] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
80 Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239. [PMID: 17299059 DOI: 10.1136/gut.2006.106781] [Cited by in Crossref: 649] [Cited by in F6Publishing: 609] [Article Influence: 43.3] [Reference Citation Analysis]
81 Rott S, Mrowietz U. The use of infliximab in dermatology. J Dtsch Dermatol Ges 2007;5:655-60. [PMID: 17659038 DOI: 10.1111/j.1610-0387.2007.06319.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
82 Lorinczy K, Miheller P, Kiss SL, Lakatos PL. [Epidemiology, predictors and clinical aspects of loss of response to biological therapy]. Orv Hetil 2012;153:163-73. [PMID: 22275731 DOI: 10.1556/OH.2012.29294] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
83 Su C, Lichtenstein GR. Are there predictors of Remicade treatment success or failure? Adv Drug Deliv Rev. 2005;57:237-245. [PMID: 15555740 DOI: 10.1016/j.addr.2004.08.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
84 Aeschlimann FA, Angst F, Hofer KD, Cannizzaro Schneider E, Schroeder-kohler S, Lauener R, van der Kleij D, Rispens T, Saurenmann RK. Prevalence of Anti-infliximab Antibodies and Their Associated Co-factors in Children with Refractory Arthritis and/or Uveitis: A Retrospective Longitudinal Cohort Study. J Rheumatol 2017;44:334-41. [DOI: 10.3899/jrheum.160072] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
85 Finckh A, Dudler J, Wermelinger F, Ciurea A, Kyburz D, Gabay C, Bas S; physicians of SCQM. Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. Joint Bone Spine 2010;77:313-8. [PMID: 20471890 DOI: 10.1016/j.jbspin.2010.02.021] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
86 Veres G, Baldassano RN, Mamula P. Infliximab therapy for pediatric Crohn's disease. Expert Opinion on Biological Therapy 2007;7:1869-80. [DOI: 10.1517/14712598.7.12.1869] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
87 Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
88 Taylor PC, Williams RO, Feldmann M. Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases. Curr Opin Biotechnol 2004;15:557-63. [PMID: 15560982 DOI: 10.1016/j.copbio.2004.09.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
89 Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004;99:878-83. [PMID: 15128354 DOI: 10.1111/j.1572-0241.2004.04148.x] [Cited by in Crossref: 275] [Cited by in F6Publishing: 231] [Article Influence: 15.3] [Reference Citation Analysis]
90 Di Sabatino A, Liberato L, Marchetti M, Biancheri P, Corazza GR. Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. Intern Emerg Med. 2011;6 Suppl 1:17-27. [PMID: 22009609 DOI: 10.1007/s11739-011-0673-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
91 Gisbert JP, Panés J. Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review. Am J Gastroenterol 2009;104:760-7. [DOI: 10.1038/ajg.2008.88] [Cited by in Crossref: 344] [Cited by in F6Publishing: 350] [Article Influence: 26.5] [Reference Citation Analysis]
92 Ginard D, Mariño Z. ¿Tengo que premedicar a todos los pacientes cuando les pongo infliximab para disminuir las reacciones infusionales y/o la inmunogenicidad? Gastroenterología y Hepatología 2008;31:542-3. [DOI: 10.1157/13127101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
93 Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, Dotan I, Chowers Y, Confino-Cohen R, Weiss B. Infliximab-Related Infusion Reactions: Systematic Review. J Crohns Colitis. 2015;9:806-815. [PMID: 26092578 DOI: 10.1093/ecco-jcc/jjv096] [Cited by in Crossref: 97] [Cited by in F6Publishing: 72] [Article Influence: 13.9] [Reference Citation Analysis]
94 Rosh JR. Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease. Curr Gastroenterol Rep 2008;10:302-7. [DOI: 10.1007/s11894-008-0060-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
95 Malviya G, Salemi S, Laganà B, Diamanti AP, D'Amelio R, Signore A. Biological therapies for rheumatoid arthritis: progress to date. BioDrugs 2013;27:329-45. [PMID: 23558378 DOI: 10.1007/s40259-013-0021-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
96 Hong DI, Bankova L, Cahill KN, Kyin T, Castells MC. Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Review of Clinical Immunology 2014;8:43-54. [DOI: 10.1586/eci.11.75] [Cited by in Crossref: 58] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
97 Qiu Y, Mao R, Chen B, Zhang S, Guo J, He Y, Zeng Z, Ben-horin S, Chen M. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis. Clinical Gastroenterology and Hepatology 2017;15:1359-1372.e6. [DOI: 10.1016/j.cgh.2017.02.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
98 Hsu L, Armstrong AW. Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response. Expert Review of Clinical Immunology 2014;9:949-58. [DOI: 10.1586/1744666x.2013.836060] [Cited by in Crossref: 37] [Cited by in F6Publishing: 16] [Article Influence: 4.6] [Reference Citation Analysis]
99 Michielan A, Martinato M, Favarin A, Zanotto V, Caccaro R, Caruso A, Sturniolo GC, D’incà R. A nurse-led accelerated procedure for infliximab infusion is well tolerated and effective in patients with inflammatory bowel disease. Digestive and Liver Disease 2015;47:372-7. [DOI: 10.1016/j.dld.2015.01.152] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
100 Domènech E, Zabana Y, Mañosa M, Garcia-planella E, Cabré E, Gassull MÀ. Infliximab Reintroduction is Not Associated to a Higher Rate of Immune-related Adverse Effects in Patients With Inflammatory Bowel Disease Initially Treated With a Three-infusion Induction Regimen. Journal of Clinical Gastroenterology 2010;44:34-7. [DOI: 10.1097/mcg.0b013e3181962dfa] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
101 Hagen JW, Magro CM, Crowson AN. Emerging Adverse Cutaneous Drug Reactions. Dermatologic Clinics 2012;30:695-730. [DOI: 10.1016/j.det.2012.06.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
102 Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johanns J, Lang Y, Sandborn WJ. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009;30:210-226. [PMID: 19392858 DOI: 10.1111/j.1365-2036.2009.04027.x] [Cited by in Crossref: 145] [Cited by in F6Publishing: 132] [Article Influence: 11.2] [Reference Citation Analysis]
103 Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs 2017;31:299-316. [PMID: 28612180 DOI: 10.1007/s40259-017-0231-8] [Cited by in Crossref: 131] [Cited by in F6Publishing: 111] [Article Influence: 32.8] [Reference Citation Analysis]
104 Feagan BG, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponich TP, Bourdages R, Macintosh DG, Dallaire C, Cohen A. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146:681-688.e1. [PMID: 24269926 DOI: 10.1053/j.gastro.2013.11.024] [Cited by in Crossref: 200] [Cited by in F6Publishing: 170] [Article Influence: 22.2] [Reference Citation Analysis]
105 Michetti P, Mottet C, Juillerat P, Pittet V, Felley C, Vader J, Gonvers J, Froehlich F. Severe and Steroid-Resistant Crohn’s Disease. Digestion 2008;76:99-108. [DOI: 10.1159/000111023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
106 Vermeire S, Gils A, Accossato P, Lula S, Marren A. Immunogenicity of biologics in inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:1756283X17750355. [PMID: 29383030 DOI: 10.1177/1756283x17750355] [Cited by in Crossref: 90] [Cited by in F6Publishing: 35] [Article Influence: 22.5] [Reference Citation Analysis]
107 Qiu Y, Chen BL, Mao R, Zhang SH, He Y, Zeng ZR, Ben-Horin S, Chen MH. Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease. J Gastroenterol 2017;52:535-54. [PMID: 28275925 DOI: 10.1007/s00535-017-1324-3] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 12.2] [Reference Citation Analysis]
108 Feuerstein JD, Cullen G, Cheifetz AS. Immune-mediated Reactions to Anti-tumor Necrosis Factors in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2015;21:1176-86. [DOI: 10.1097/mib.0000000000000279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
109 Hinojosa J, Gomollón F, García S, Bastida G, Cabriada JL, Saro C, Ceballos D, Peñate M, Gassull MA; Spanish Scientific Group on Crohn's Disease and Ulcerative Colitis. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007;25:409-18. [PMID: 17269996 DOI: 10.1111/j.1365-2036.2006.03232.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 68] [Article Influence: 4.2] [Reference Citation Analysis]
110 Richter JA, Bickston SJ. Infliximab use in luminal Crohn's disease. Gastroenterol Clin North Am 2006;35:775-93. [PMID: 17129813 DOI: 10.1016/j.gtc.2006.09.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
111 Renna S, Cottone M, Orlando A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9675-9690 [PMID: 25110407 DOI: 10.3748/wjg.v20.i29.9675] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
112 D’Haens G. Anti-TNF treatment in Crohn’s disease: toward tailored therapy? Am J Gastroenterol. 2010;105:1140-1141. [PMID: 20445512 DOI: 10.1038/ajg.2010.15] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
113 Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther. 2007;25:675-680. [PMID: 17311600 DOI: 10.1111/j.1365-2036.2007.03254.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 3.1] [Reference Citation Analysis]
114 Bots SJ, Parker CE, Brandse JF, Löwenberg M, Feagan BG, Sandborn WJ, Jairath V, D'Haens G, Vande Casteele N. Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. BioDrugs 2021;35:715-33. [PMID: 34797516 DOI: 10.1007/s40259-021-00507-5] [Reference Citation Analysis]
115 Kamm MA. Review article: chronic active disease and maintaining remission in Crohn's disease. Aliment Pharmacol Ther 2004;20 Suppl 4:102-5. [PMID: 15352904 DOI: 10.1111/j.1365-2036.2004.02052.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
116 Khanna R, Feagan BG. Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD. Curr Treat Options Gastro 2014;12:76-89. [DOI: 10.1007/s11938-013-0005-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
117 Imaeda H, Andoh A, Fujiyama Y. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol. 2012;47:136-143. [PMID: 21953314 DOI: 10.1007/s00535-011-0474-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
118 Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn‘s disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254. [PMID: 16931170 DOI: 10.1016/j.cgh.2006.06.025] [Cited by in Crossref: 446] [Cited by in F6Publishing: 413] [Article Influence: 27.9] [Reference Citation Analysis]
119 Larsen L, Jess T, Drewes AM, Dige A, Fallingborg J, Jacobsen BA, Aagaard B, Agnholt J. Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. European Journal of Gastroenterology & Hepatology 2019;31:964-7. [DOI: 10.1097/meg.0000000000001440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Oussalah A, Roblin X, Laharie D, Filippi J, Flamant M, Faure P, Phelip J, Bigard M, Peyrin-biroulet L. Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey. Alimentary Pharmacology & Therapeutics 2009;30:854-63. [DOI: 10.1111/j.1365-2036.2009.4097.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
121 Molander P, Färkkilä M, Salminen K, Kemppainen H, Blomster T, Koskela R, Jussila A, Rautiainen H, Nissinen M, Haapamäki J. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission. Inflamm Bowel Dis. 2014;20:1021-1028. [PMID: 24798636 DOI: 10.1097/mib.0000000000000052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
122 Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231. [PMID: 17229796 DOI: 10.1136/gut.2006.099978] [Cited by in Crossref: 419] [Cited by in F6Publishing: 387] [Article Influence: 27.9] [Reference Citation Analysis]
123 Friesen CA, Calabro C, Christenson K, Carpenter E, Welchert E, Daniel JF, Haslag S, Roberts CC. Safety of Infliximab Treatment in Pediatric Patients with Inflammatory Bowel Disease: . Journal of Pediatric Gastroenterology and Nutrition 2004;39:265-9. [DOI: 10.1097/00005176-200409000-00008] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
124 Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut 2007;56:1181-3. [PMID: 17698862 DOI: 10.1136/gut.2006.115980] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
125 Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum. 2006;49:1837-1841. [PMID: 17041753 DOI: 10.1007/s10350-006-0656-5] [Cited by in Crossref: 126] [Cited by in F6Publishing: 95] [Article Influence: 8.4] [Reference Citation Analysis]
126 Roblin X, Marotte H, Leclerc M, Del Tedesco E, Phelip JM, Peyrin-Biroulet L, Paul S. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. J Crohns Colitis. 2015;9:525-531. [PMID: 25895875 DOI: 10.1093/ecco-jcc/jjv061] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 9.0] [Reference Citation Analysis]
127 Rott S, Mrowietz U. Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies. BMJ 2005;330:716-20. [PMID: 15790644 DOI: 10.1136/bmj.330.7493.716] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
128 Juillerat P, Felley C, Mottet C, Froehlich F, Vader J, Burnand B, Gonvers J, Michetti P. Drug Safety in the Treatment of Crohn’s Disease. Digestion 2005;71:8-12. [DOI: 10.1159/000083865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
129 Domènech E, Esteve M, Gomollón F, Hinojosa J, Panés J, Obrador A, Gassull M. Recomendaciones GETECCU-2005 para el uso de infliximab (Remicade®) en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2005;28:126-34. [DOI: 10.1157/13072012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
130 Peyrin-Biroulet L. [Anti-TNF therapy and Crohn’s disease]. Gastroenterol Clin Biol. 2008;32:478-481. [PMID: 18439777 DOI: 10.1016/j.gcb.2008.03.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
131 van Assche G. Emerging drugs to treat Crohn’s disease. Expert Opinion on Emerging Drugs 2007;12:49-59. [DOI: 10.1517/14728214.12.1.49] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
132 Orlando A, Mocciaro F, Civitavecchia G, Scimeca D, Cottone M. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease. Digestive and Liver Disease 2008;40:S236-46. [DOI: 10.1016/s1590-8658(08)60532-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
133 Pithadia AB, Jain S. Treatment of inflammatory bowel disease (IBD). Pharmacol Rep. 2011;63:629-642. [PMID: 21857074 DOI: 10.1016/s1734-1140(11)70575-8] [Cited by in Crossref: 135] [Cited by in F6Publishing: 57] [Article Influence: 12.3] [Reference Citation Analysis]
134 Bremner AR, Griffiths DM, Beattie RM. Current therapy of ulcerative colitis in children. Expert Opin Pharmacother 2004;5:37-53. [PMID: 14680434 DOI: 10.1517/14656566.5.1.37] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
135 Minar P, Saeed SA, Afreen M, Kim MO, Denson LA. Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr 2016;62:715-22. [PMID: 26551317 DOI: 10.1097/MPG.0000000000001029] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
136 Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, Rutgeerts P. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol. 2004;2:542-553. [PMID: 15224278 DOI: 10.1016/s1542-3565(04)00238-1] [Cited by in Crossref: 429] [Cited by in F6Publishing: 98] [Article Influence: 23.8] [Reference Citation Analysis]
137 Vultaggio A, Nencini F, Pratesi S, Petroni G, Maggi E, Matucci A. Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions. J Interferon Cytokine Res 2014;34:946-52. [PMID: 25493962 DOI: 10.1089/jir.2012.0139] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
138 Ye BD, Yang S, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim Y, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Guidelines for the Management of Crohn's Disease. Intest Res 2012;10:26. [DOI: 10.5217/ir.2012.10.1.26] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
139 Mcnamara D, Brophy S, Hyland J. Perianal Crohn's disease and infliximab therapy. The Surgeon 2004;2:258-63. [DOI: 10.1016/s1479-666x(04)80094-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
140 Fefferman DS, Lodhavia PJ, Alsahli M, Falchuk KR, Peppercorn MA, Shah SA, Farrell RJ. Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease. Inflamm Bowel Dis. 2004;10:346-351. [PMID: 15475741 DOI: 10.1097/00054725-200407000-00004] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.0] [Reference Citation Analysis]
141 Ruemmele FM. Infliximab: How to Use It in Pediatric Crohn’s Disease: . Journal of Pediatric Gastroenterology and Nutrition 2004;39:12-4. [DOI: 10.1097/00005176-200407000-00004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
142 Nguyen GC, Harris ML, Dassopoulos T. Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2006;8:499-505. [PMID: 17105689 DOI: 10.1007/s11894-006-0040-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
143 Ito T, Sonoda K, Hijioka K, Fujimoto T, Ishibashi T. Acquired resistance to infliximab against uveitis due to Behçet’s disease after one year of administration. Jpn J Ophthalmol 2010;54:502-4. [DOI: 10.1007/s10384-010-0859-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
144 Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol. 2008;103:944-948. [PMID: 18028512 DOI: 10.1111/j.1572-0241.2007.01638.x] [Cited by in Crossref: 119] [Cited by in F6Publishing: 117] [Article Influence: 7.9] [Reference Citation Analysis]
145 Alt C, Lam JS, Harrison MT, Kershaw KM, Samuelsson S, Toll L, D'Andrea A. Nociceptin/orphanin FQ inhibition with SB612111 ameliorates dextran sodium sulfate-induced colitis. Eur J Pharmacol 2012;683:285-93. [PMID: 22449384 DOI: 10.1016/j.ejphar.2012.03.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
146 Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, Patel J. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut. 2004;53:1485-1493. [PMID: 15361500 DOI: 10.1136/gut.2003.035253] [Cited by in Crossref: 119] [Cited by in F6Publishing: 107] [Article Influence: 6.6] [Reference Citation Analysis]
147 Sadowski DC, Bernstein CN, Bitton A, Croitoru K, Fedorak RN, Griffiths A; CAG Crohn's Consensus Group. Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol 2009;23:185-202. [PMID: 19319383 DOI: 10.1155/2009/201430] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
148 Rozette NA, Hellauer CM, Mckee C, Vazifedan T, Gabriel CA, Dice JE, Yokois NU. Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population. Inflammatory Bowel Diseases 2018;24:2007-14. [DOI: 10.1093/ibd/izy093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
149 Cappello M, Morreale GC. The Role of Laboratory Tests in Crohn's Disease. Clin Med Insights Gastroenterol. 2016;9:51-62. [PMID: 27656094 DOI: 10.4137/cgast.s38203] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
150 Van Assche G, Lewis JD, Lichtenstein GR, Loftus EV, Ouyang Q, Panes J, Siegel CA, Sandborn WJ, Travis SP, Colombel JF. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 2011;106:1594-602; quiz 1593, 1603. [PMID: 21844919 DOI: 10.1038/ajg.2011.211] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
151 Picoraro J, Winberry G, Siegel CA, El-Matary W, Moses J, Grossman A, Park KT. Premedication Use Before Infliximab Administration: A Cross-sectional Analysis. Inflamm Bowel Dis 2017;23:174-80. [PMID: 28002131 DOI: 10.1097/MIB.0000000000001002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.8] [Reference Citation Analysis]
152 Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34:51-58. [PMID: 21535447 DOI: 10.1111/j.1365-2036.2011.04682.x] [Cited by in Crossref: 109] [Cited by in F6Publishing: 104] [Article Influence: 9.9] [Reference Citation Analysis]
153 Hausmann OV, Seitz M, Villiger PM, Pichler WJ. The complex clinical picture of side effects to biologicals. Med Clin North Am 2010;94:791-804, xi-ii. [PMID: 20609863 DOI: 10.1016/j.mcna.2010.03.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
154 Griffiths OR, Landon J, Coxon RE, Morris K, James P, Adams R. Inflammatory bowel disease and targeted oral anti-TNFα therapy. Adv Protein Chem Struct Biol 2020;119:157-98. [PMID: 31997768 DOI: 10.1016/bs.apcsb.2019.08.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
155 Nakamura K, Honda K, Mizutani T, Akiho H, Harada N. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol 2006; 12(29): 4628-4635 [PMID: 16937430 DOI: 10.3748/wjg.v12.i29.4628] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 71] [Article Influence: 4.6] [Reference Citation Analysis]
156 Rojko JL, Evans MG, Price SA, Han B, Waine G, Dewitte M, Haynes J, Freimark B, Martin P, Raymond JT, Evering W, Rebelatto MC, Schenck E, Horvath C. Formation, Clearance, Deposition, Pathogenicity, and Identification of Biopharmaceutical-related Immune Complexes: Review and Case Studies. Toxicol Pathol 2014;42:725-64. [DOI: 10.1177/0192623314526475] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 11.0] [Reference Citation Analysis]
157 Yamamoto-furusho J, Bosques-padilla F, de-Paula J, Galiano M, Ibañez P, Juliao F, Kotze P, Rocha J, Steinwurz F, Veitia G, Zaltman C. Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México 2017;82:46-84. [DOI: 10.1016/j.rgmx.2016.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
158 Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA. Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay: authors’ reply: Letters to the Editors. Alimentary Pharmacology & Therapeutics 2011;34:404-5. [DOI: 10.1111/j.1365-2036.2011.04748.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
159 Lie MR, Peppelenbosch MP, West RL, Zelinkova Z, van der Woude CJ. Adalimumab in Crohn’s disease patients: pharmacokinetics in the first 6 months of treatment. Aliment Pharmacol Ther. 2014;40:1202-1208. [PMID: 25263077 DOI: 10.1111/apt.12969] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
160 Grimpen F, Pavli P. Advances in the management of inflammatory bowel disease. Intern Med J 2010;40:258-64. [PMID: 20059603 DOI: 10.1111/j.1445-5994.2010.02163.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
161 van Brummelen EM, Ros W, Wolbink G, Beijnen JH, Schellens JH. Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges. Oncologist 2016;21:1260-8. [PMID: 27440064 DOI: 10.1634/theoncologist.2016-0061] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
162 Díaz-ley B, Guhl G, Fernández-herrera J. Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Primera parte: infliximab y adalimumab. Actas Dermo-Sifiliográficas 2007;98:657-78. [DOI: 10.1016/s0001-7310(07)70159-x] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
163 Isaacs KL. Crohn's disease of the esophagus. Curr Treat Options Gastroenterol 2007;10:61-70. [PMID: 17298766 DOI: 10.1007/s11938-007-0058-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
164 Weisshof R, Ungar B, Blatt A, Dahan A, Pressman S, Waterman M, Kopylov U, Ben-Horin S, Chowers Y. Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease: Distinct Clinical Implications Revealed by a Novel Assay.Inflamm Bowel Dis. 2016;22:1655-1661. [PMID: 27120567 DOI: 10.1097/MIB.0000000000000797] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
165 Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005;25:1181-92. [PMID: 16164393 DOI: 10.1592/phco.2005.25.9.1181] [Cited by in Crossref: 93] [Cited by in F6Publishing: 77] [Article Influence: 5.5] [Reference Citation Analysis]
166 Lelong J, Duburque C, Fournier C, Colombel J, Desreumaux P, Tonnel A, Wallaert B. Accoutumance médicamenteuse à l’infliximab dans la maladie de Crohn. Revue des Maladies Respiratoires 2005;22:239-46. [DOI: 10.1016/s0761-8425(05)85477-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
167 Aloi M, Nuti F, Stronati L, Cucchiara S. Advances in the medical management of paediatric IBD. Nat Rev Gastroenterol Hepatol. 2014;11:99-108. [PMID: 23958601 DOI: 10.1038/nrgastro.2013.158] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
168 Van Assche G, Vermeire S, Rutgeerts P. Medical treatment of inflammatory bowel diseases. Curr Opin Gastroenterol. 2005;21:443-447. [PMID: 15930985 DOI: 10.1097/01.mog.0000166752.94169.ca] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
169 Tobin AM, Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 2005;19:47-57. [PMID: 15691217 DOI: 10.2165/00063030-200519010-00006] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 3.8] [Reference Citation Analysis]
170 Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L, Van Huysse J, Demetter P, Steidler L, Remaut E. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 2010;3:49-56. [PMID: 19794409 DOI: 10.1038/mi.2009.116] [Cited by in Crossref: 156] [Cited by in F6Publishing: 142] [Article Influence: 12.0] [Reference Citation Analysis]
171 Camilleri M. GI clinical research 2002–2003: the year in review. Clinical Gastroenterology and Hepatology 2003;1:415-20. [DOI: 10.1016/s1542-3565(03)00220-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
172 Guiotto C, Daperno M, Frigerio F, Vizzini M, Cerruti R, Ercole E, Cosimato M, Lavagna A, Germano L, Migliardi M, Rocca R. Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease. Digestive and Liver Disease 2016;48:138-43. [DOI: 10.1016/j.dld.2015.10.023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
173 Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R, Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, Louis E. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease. J Crohns Colitis. 2018;12:17-31. [PMID: 28981623 DOI: 10.1093/ecco-jcc/jjx101] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 17.8] [Reference Citation Analysis]
174 Ono K, Nimura S, Nishinakagawa T, Hideshima Y, Enjyoji M, Nabeshima K, Nakashima M. Sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice. Exp Ther Med 2014;7:573-8. [PMID: 24520247 DOI: 10.3892/etm.2013.1456] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
175 D’haens G, Hlavaty T. Advances in medical therapy for Crohn’s disease. Curr Gastroenterol Rep 2004;6:496-505. [DOI: 10.1007/s11894-004-0072-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
176 Ayyala US, Padilla ML. Diagnosis and treatment of hepatic sarcoidosis. Curr Treat Options Gastroenterol. 2006;9:475-483. [PMID: 17081481 DOI: 10.1007/s11938-006-0004-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
177 Gold SL, Cohen-mekelburg S, Schneider Y, Shen N, Faggen A, Rupert A, Scherl EJ, Bosworth B, Steinlauf A. Premedication Use in Preventing Acute Infliximab Infusion Reactions in Patients with Inflammatory Bowel Disease: A Single Center Cohort Study. Inflammatory Bowel Diseases 2017;23:1882-9. [DOI: 10.1097/mib.0000000000001189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
178 Vermeire S, Van Assche G, Rutgeerts P. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract Res Clin Gastroenterol. 2009;23:101-112. [PMID: 19258190 DOI: 10.1016/j.bpg.2008.12.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
179 Veres G, Baldassano RN, Mamula P. Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease: . Drugs 2007;67:1703-23. [DOI: 10.2165/00003495-200767120-00005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
180 Levin EC, Gupta R, Brown G, Malakouti M, Koo J. Biologic fatigue in psoriasis. Journal of Dermatological Treatment 2013;25:78-82. [DOI: 10.3109/09546634.2013.826341] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
181 Nguyen DL, Flores S, Sassi K, Bechtold ML, Nguyen ET, Parekh NK. Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease. Ther Adv Chronic Dis 2015;6:147-54. [PMID: 25954499 DOI: 10.1177/2040622315579621] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
182 Mould DR, Dubinsky MC. Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies. J Clin Pharmacol. 2015;55 Suppl 3:S51-S59. [PMID: 25707964 DOI: 10.1002/jcph.370] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 5.1] [Reference Citation Analysis]
183 Li Y, Stocchi L, Rui Y, Remzi FH, Shen B. Comparable outcomes of the consistent use versus switched use of anti- tumor necrosis factor agents in postoperative recurrent Crohn’s disease following ileocolonic resection. Int J Colorectal Dis 2016;31:1751-8. [DOI: 10.1007/s00384-016-2632-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
184 Bressler B, Sands BE. Review article: Medical therapy for fistulizing Crohn’s disease. Aliment Pharmacol Ther. 2006;24:1283-1293. [PMID: 17059510 DOI: 10.1111/j.1365-2036.2006.03126.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
185 Colombel JF, Feagan BG, Sandborn WJ, Van Assche G, Robinson AM. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:349-358. [PMID: 22021134 DOI: 10.1002/ibd.21831] [Cited by in Crossref: 91] [Cited by in F6Publishing: 82] [Article Influence: 8.3] [Reference Citation Analysis]
186 Tran-Minh ML, Gornet JM, Maillet M, Houze P, Simon M, McLellan P, Hassid D, Vivier-Chicoteau J, Baudry C, Hammoudi N, Allez M. Safety of Hydrocortisone Premedication Discontinuation in Patients with Inflammatory Bowel Disease on Maintenance Therapy with Infliximab: a Prospective Clinical and Pharmacological Study. J Crohns Colitis 2021;15:742-8. [PMID: 33205193 DOI: 10.1093/ecco-jcc/jjaa231] [Reference Citation Analysis]
187 Lee LY, Sanderson JD, Irving PM. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. Eur J Gastroenterol Hepatol. 2012;24:1078-1085. [PMID: 22647738 DOI: 10.1097/meg.0b013e32835558cf] [Cited by in Crossref: 47] [Cited by in F6Publishing: 12] [Article Influence: 5.2] [Reference Citation Analysis]
188 Vultaggio A, Perlato M, Nencini F, Vivarelli E, Maggi E, Matucci A. How to Prevent and Mitigate Hypersensitivity Reactions to Biologicals Induced by Anti-Drug Antibodies? Front Immunol 2021;12:765747. [PMID: 34790200 DOI: 10.3389/fimmu.2021.765747] [Reference Citation Analysis]
189 Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cézard JP. Clinical and biological consequences of immunization to infliximab in pediatric Crohn’s disease. Clin Immunol. 2006;118:11-19. [PMID: 16125467 DOI: 10.1016/j.clim.2005.07.010] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 4.5] [Reference Citation Analysis]
190 Atzeni F, Talotta R, Salaffi F, Cassinotti A, Varisco V, Battellino M, Ardizzone S, Pace F, Sarzi-Puttini P. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev. 2013;12:703-708. [PMID: 23207283 DOI: 10.1016/j.autrev.2012.10.021] [Cited by in Crossref: 130] [Cited by in F6Publishing: 120] [Article Influence: 13.0] [Reference Citation Analysis]
191 Danese S, Fiorino G, Reinisch W. Review article: Causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapy. Aliment Pharmacol Ther. 2011;34:1-10. [PMID: 21539588 DOI: 10.1111/j.1365-2036.2011.04679.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 88] [Article Influence: 8.0] [Reference Citation Analysis]
192 Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Blank M, Lang Y. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18:201-211. [PMID: 21484965 DOI: 10.1002/ibd.21697] [Cited by in Crossref: 133] [Cited by in F6Publishing: 119] [Article Influence: 12.1] [Reference Citation Analysis]
193 Duron C, Goutte M, Pereira B, Bommelaer G, Buisson A. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy. European Journal of Gastroenterology & Hepatology 2015;27:705-11. [DOI: 10.1097/meg.0000000000000354] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
194 Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis. 2010;16:1898-1904. [PMID: 20310016 DOI: 10.1002/ibd.21259] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
195 Miheller P, Lakatos PL, Horváth G, Molnár T, Szamosi T, Czeglédi Z, Salamon A, Czimmer J, Rumi G, Palatka K. Efficacy and safety of infliximab induction therapy in Crohn’s Disease in Central Europe--a Hungarian nationwide observational study. BMC Gastroenterol. 2009;9:66. [PMID: 19740450 DOI: 10.1186/1471-230x-9-66] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
196 Jullien D. Anticorps anti-médicament, auto-anticorps et traitements biologiques du psoriasis. Annales de Dermatologie et de Vénéréologie 2012;139:S58-67. [DOI: 10.1016/s0151-9638(12)70112-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
197 Van Assche G, Vermeire S, Rutgeerts P. Management of loss of response to anti-TNF drugs: Change the dose or change the drug? Journal of Crohn's and Colitis 2008;2:348-51. [DOI: 10.1016/j.crohns.2008.05.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
198 Hlavaty T, Ferrante M, Henckaerts L, Pierik M, Rutgeerts P, Vermeire S. Predictive model for the outcome of infliximab therapy in Crohn’s disease based on apoptotic pharmacogenetic index and clinical predictors. Inflamm Bowel Dis. 2007;13:372-379. [PMID: 17206723 DOI: 10.1002/ibd.20024] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 3.4] [Reference Citation Analysis]
199 Ye BD, Yang SK, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim YH, Lee H. [Guidelines for the management of Crohn’s disease]. Korean J Gastroenterol. 2012;59:141-179. [PMID: 22387837 DOI: 10.4166/kjg.2012.59.2.141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
200 Tamboli CP. Current Medical Therapy for Chronic Inflammatory Bowel Diseases. Surgical Clinics of North America 2007;87:697-725. [DOI: 10.1016/j.suc.2007.03.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
201 Juillerat P, Pittet V, Felley C, Mottet C, Froehlich F, Vader JP, Gonvers JJ, Michetti P. Drug safety in Crohn's disease therapy. Digestion 2007;76:161-8. [PMID: 18239408 DOI: 10.1159/000111031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
202 Kamm MA. Review article: biological drugs in Crohn's disease. Aliment Pharmacol Ther 2006;24:80-9. [DOI: 10.1111/j.1365-2036.2006.03066.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
203 Michetti P, Mottet C, Juillerat P, Felley C, Vader JP, Burnand B, Gonvers JJ, Froehlich F. Severe and steroid-resistant Crohn's disease. Digestion 2005;71:19-25. [PMID: 15711044 DOI: 10.1159/000083867] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
204 Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs. 2004;64:1767-1777. [PMID: 15301561 DOI: 10.2165/00003495-200464160-00004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 3.0] [Reference Citation Analysis]
205 Scott FI, Lichtenstein GR. Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2014;12:59-75. [PMID: 24452768 DOI: 10.1007/s11938-013-0004-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
206 Belhassan M, Zeitoun J, Lefevre JH, Charachon A, Amiot A, Le Baleur Y, Sobhani I, Delchier J. Infliximab infusion time in patients with inflammatory bowel diseases: Is longer really safer? Clinics and Research in Hepatology and Gastroenterology 2013;37:189-92. [DOI: 10.1016/j.clinre.2012.07.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
207 Gisbert JP, Marín AC, Chaparro M. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Am J Gastroenterol 2016;111:632-47. [PMID: 27002797 DOI: 10.1038/ajg.2016.54] [Cited by in Crossref: 86] [Cited by in F6Publishing: 71] [Article Influence: 14.3] [Reference Citation Analysis]
208 Casellas i Jordà F. [TNF-alpha inhibitors in inflammatory bowel disease]. Med Clin (Barc) 2004;123:627-34. [PMID: 15546523 DOI: 10.1016/s0025-7753(04)74622-9] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
209 Mosli MH, Sandborn WJ, Kim RB, Khanna R, Al-Judaibi B, Feagan BG. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol 2014;109:994-1004. [PMID: 24842338 DOI: 10.1038/ajg.2014.110] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
210 Kuhbacher T, Fölsch U. Practical guidelines for the treatment of inflammatory bowel disease. World J Gastroenterol 2007; 13(8): 1149-1155 [PMID: 17451192 DOI: 10.3748/wjg.v13.i8.1149] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
211 Van Assche G, Magdelaine-Beuzelin C, D’Haens G, Baert F, Noman M, Vermeire S, Ternant D, Watier H, Paintaud G, Rutgeerts P. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134:1861-1868. [PMID: 18440315 DOI: 10.1053/j.gastro.2008.03.004] [Cited by in Crossref: 375] [Cited by in F6Publishing: 322] [Article Influence: 26.8] [Reference Citation Analysis]
212 González-lama Y, López-san Román A, Marín-jiménez I, Casis B, Vera I, Bermejo F, Lázaro Pérez-calle J, Taxonera C, Martínez-silva F, Menchén L, Martínez-montiel P, Calvo M, Antonio Carneros J, López P, Luis Mendoza J, María Milicua J, Huerta A, Sánchez F, Abreu L, López-palacios N, Maté J, Gisberta JP. Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. Gastroenterología y Hepatología 2008;31:421-6. [DOI: 10.1157/13125587] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
213 Cassinotti A, Ardizzone S, Porro GB. Adalimumab for the treatment of Crohn's disease. Biologics. 2008;2:763-777. [PMID: 19707457 DOI: 10.2147/btt.s3292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 0.5] [Reference Citation Analysis]
214 Courbette O, Aupiais C, Viala J, Hugot J, Roblin X, Candon S, Louveau B, Chatenoud L, Martinez-vinson C. Trough Levels of Infliximab at Week 6 Are Predictive of Remission at Week 14 in Pediatric Crohn's Disease. Journal of Pediatric Gastroenterology & Nutrition 2020;70:310-7. [DOI: 10.1097/mpg.0000000000002536] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
215 Pallagi-Kunstár &, Farkas K, Szepes Z, Nagy F, Szűcs M, Kui R, Gyulai R, Bálint A, Wittmann T, Molnár T. Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol 2014; 20(17): 5031-5035 [PMID: 24833846 DOI: 10.3748/wjg.v20.i17.5031] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
216 Gisbert JP, Marín AC, Chaparro M. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther. 2015;42:391-405. [PMID: 26075832 DOI: 10.1111/apt.13276] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 8.0] [Reference Citation Analysis]
217 Lim AW, Panaccione R, Seow CH. Exploring the role of monitoring anti-TNFα drug and antibody levels in the management of inflammatory bowel disease. Therap Adv Gastroenterol 2011;4:145-51. [PMID: 21694815 DOI: 10.1177/1756283X10382816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
218 Parsi MA, Lashner BA. Safety of infliximab: primum non nocere. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Inflamm Bowel Dis 2004;10:486-7. [PMID: 15475765 DOI: 10.1097/00054725-200407000-00028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
219 Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91:635-646. [PMID: 22357456 DOI: 10.1038/clpt.2011.328] [Cited by in Crossref: 321] [Cited by in F6Publishing: 284] [Article Influence: 32.1] [Reference Citation Analysis]
220 Lee TW, Singh R, Fedorak RN. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study: A 1-h infliximab infusion during maintenance therapy is safe. Alimentary Pharmacology & Therapeutics 2011;34:181-7. [DOI: 10.1111/j.1365-2036.2011.04699.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
221 Devlin SM, Cheifetz AS, Siegel CA. Patient-Specific Approach to Combination Versus Monotherapy with the Use of Antitumor Necrosis Factor α Agents for Inflammatory Bowel Disease. Gastroenterology Clinics of North America 2012;41:411-28. [DOI: 10.1016/j.gtc.2012.01.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
222 Bern EM, Bousvaros A. Loss of response to biologics versus increased risk of lymphoma in children with inflammatory bowel disease: the clinician’s conundrum. Expert Review of Clinical Immunology 2014;9:117-27. [DOI: 10.1586/eci.12.97] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
223 Augustsson J, Eksborg S, Ernestam S, Gullström E, van Vollenhoven R. Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:1462-6. [PMID: 17502359 DOI: 10.1136/ard.2007.070771] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
224 Hare NC, Arnott ID, Satsangi J. Therapeutic options in acute severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;2:357-70. [DOI: 10.1586/17474124.2.3.357] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
225 Pauwels RWM, van der Woude CJ, Nieboer D, Steyerberg EW, Casanova MJ, Gisbert JP, Kennedy NA, Lees CW, Louis E, Molnár T, Szántó K, Leo E, Bots S, Downey R, Lukas M, Lin WC, Amiot A, Lu C, Roblin X, Farkas K, Seidelin JB, Duijvestein M, D'Haens GR, de Vries AC; CEASE Study Group. Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00347-5. [PMID: 33933376 DOI: 10.1016/j.cgh.2021.03.037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
226 Stickler M, Reddy A, Xiong JM, Wong MH, Akamatsu Y, Hinton PR, Harding FA. Design, creation and in vitro testing of a reduced immunogenicity humanized anti-CD25 monoclonal antibody that retains functional activity. Protein Eng Des Sel 2019;32:543-54. [PMID: 32725169 DOI: 10.1093/protein/gzaa017] [Reference Citation Analysis]
227 Eisenberg S. Biologic Therapy. Journal of Infusion Nursing 2012;35:301-13. [DOI: 10.1097/nan.0b013e31826579aa] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
228 Mantzaris GJ, Viazis N, Petraki K, Papamichael K, Theodoropoulos I, Roussos A, Karakoidas C, Koilakou S, Raptis N, Smyrnidis A, Agalos G, Karamanolis DG. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab. European Journal of Gastroenterology & Hepatology 2009;21:1042-8. [DOI: 10.1097/meg.0b013e32832937e3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
229 Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Current Opinion in Allergy & Clinical Immunology 2011;11:262-8. [DOI: 10.1097/aci.0b013e3283464bcd] [Cited by in Crossref: 52] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
230 Komaki Y, Komaki F, Sakuraba A, Cohen R. Approach to Optimize Anti-TNF-α Therapy in Patients With IBD. Curr Treat Options Gastroenterol. 2016;14:83-90. [PMID: 26872815 DOI: 10.1007/s11938-016-0079-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
231 Oussalah A, Laclotte C, Chevaux JB, Bensenane M, Babouri A, Serre AA, Boucekkine T, Roblin X, Bigard MA, Peyrin-Biroulet L. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008;28:966-72. [PMID: 18652603 DOI: 10.1111/j.1365-2036.2008.03811.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 4.4] [Reference Citation Analysis]
232 Calafat M, Mañosa M, Ricart E, Nos P, Iglesias-Flores E, Vera I, López-SanRomán A, Guardiola J, Taxonera C, Mínguez M, Martín-Arranz MD, de Castro L, de Francisco R, Rivero M, Garcia-Planella E, Calvet X, García-López S, Márquez L, Gomollón F, Barrio J, Esteve M, Muñoz F, Gisbert JP, Gutiérrez A, Hinojosa J, Argüelles-Arias F, Busquets D, Bujanda L, Pérez-Calle JL, Sicilia B, Merino O, Martínez P, Bermejo F, Lorente R, Barreiro-de Acosta M, Rodríguez C, García-Sepulcre MF, Monfort D, Cañete F, Domènech E; ENEIDA Study Group of GETECCU. Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry. J Crohns Colitis 2021:jjab213. [PMID: 34864947 DOI: 10.1093/ecco-jcc/jjab213] [Reference Citation Analysis]
233 Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007;46:645-60. [PMID: 17655372 DOI: 10.2165/00003088-200746080-00002] [Cited by in Crossref: 166] [Cited by in F6Publishing: 144] [Article Influence: 11.1] [Reference Citation Analysis]
234 Adler J, Sandberg KC, Shpeen BH, Eder SJ, Dhanani M, Clark SJ, Freed GL. Variation in infliximab administration practices in the treatment of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013;57:35-8. [PMID: 23459317 DOI: 10.1097/MPG.0b013e31828f1ea2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
235 Kevans D, Keegan D, Mulcahy HE, O'donoghue DP. Infliximab therapy in Crohn's disease: a pragmatic approach? Aliment Pharmacol Ther 2006;24:351-9. [DOI: 10.1111/j.1365-2036.2006.02979.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
236 Nencini F, Vultaggio A, Pratesi S, Cammelli D, Milla M, Fiori G, Bagnoli S, Prignano F, Romagnani S, Maggi E, Matucci A. The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders. The Journal of Allergy and Clinical Immunology: In Practice 2018;6:2065-2072.e2. [DOI: 10.1016/j.jaip.2018.04.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
237 Kozuch PL, Hanauer SB. General Principles and Pharmacology of Biologics in Inflammatory Bowel Disease. Gastroenterology Clinics of North America 2006;35:757-73. [DOI: 10.1016/j.gtc.2006.09.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
238 Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-83; quiz 464, 484. [PMID: 19174807 DOI: 10.1038/ajg.2008.168] [Cited by in Crossref: 606] [Cited by in F6Publishing: 516] [Article Influence: 46.6] [Reference Citation Analysis]
239 Davda J, Declerck P, Hu-Lieskovan S, Hickling TP, Jacobs IA, Chou J, Salek-Ardakani S, Kraynov E. Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. J Immunother Cancer 2019;7:105. [PMID: 30992085 DOI: 10.1186/s40425-019-0586-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 12.0] [Reference Citation Analysis]
240 Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013;108:40-7; quiz 48. [PMID: 23147525 DOI: 10.1038/ajg.2012.363] [Cited by in Crossref: 243] [Cited by in F6Publishing: 224] [Article Influence: 24.3] [Reference Citation Analysis]
241 Loftus EV, Johnson SJ, Wang ST, Wu E, Mulani PM, Chao J. Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease. Inflamm Bowel Dis. 2011;17:127-140. [PMID: 20848523 DOI: 10.1002/ibd.21341] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
242 Louis E, Mary J, Vernier–massouille G, Grimaud J, Bouhnik Y, Laharie D, Dupas J, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel J, Lemann M. Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped. Gastroenterology 2012;142:63-70.e5. [DOI: 10.1053/j.gastro.2011.09.034] [Cited by in Crossref: 396] [Cited by in F6Publishing: 351] [Article Influence: 39.6] [Reference Citation Analysis]
243 Rodríguez-Moranta F, Soriano-Izquierdo A, Guardiola J. [Current status of treatment of inflammatory bowel disease]. Cir Esp 2007;82:254-9. [PMID: 18021623 DOI: 10.1016/s0009-739x(07)71722-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
244 Gagniere C, Beaugerie L, Pariente B, Seksik P, Amiot A, Abitbol V, Allez M, Cosnes J, Sokol H. Benefit of Infliximab Reintroduction after Successive Failure of Infliximab and Adalimumab in Crohn's Disease. Journal of Crohn's and Colitis 2015;9:349-55. [DOI: 10.1093/ecco-jcc/jju024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
245 Pascher A, Klupp J. Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: new applications for TNFalpha inhibitors? BioDrugs 2005;19:211-31. [PMID: 16128605 DOI: 10.2165/00063030-200519040-00002] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 3.3] [Reference Citation Analysis]
246 Faubion WA, Bousvaros A. Medical Therapy for Refractory Pediatric Crohn’s Disease. Clinical Gastroenterology and Hepatology 2006;4:1199-213. [DOI: 10.1016/j.cgh.2006.05.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
247 Greifer MK, Markowitz JF. Update in the treatment of paediatric ulcerative colitis. Expert Opin Pharmacother 2006;7:1907-18. [PMID: 17020417 DOI: 10.1517/14656566.7.14.1907] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
248 Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 2004;38:502-8. [PMID: 15097438 DOI: 10.1097/00005176-200405000-00008] [Cited by in Crossref: 93] [Cited by in F6Publishing: 84] [Article Influence: 5.2] [Reference Citation Analysis]
249 Vultaggio A, Matucci A, Parronchi P, Rossi O, Palandri F, Romagnani S, Maggi E. Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience. Int J Immunopathol Pharmacol 2008;21:367-74. [PMID: 18547481 DOI: 10.1177/039463200802100214] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
250 Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther 2005;21:373-84. [PMID: 15709987 DOI: 10.1111/j.1365-2036.2005.02336.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
251 Nuij VJAA, Peppelenbosch MP, van der Woude CJ, Fuhler GM. Genetic polymorphism in ATG16L1 gene is associated with adalimumab use in inflammatory bowel disease. J Transl Med 2017;15:248. [PMID: 29228965 DOI: 10.1186/s12967-017-1355-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
252 Saito K, Nawata M, Iwata S, Tokunaga M, Tanaka Y. Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus. Rheumatology 2005;44:1462-4. [DOI: 10.1093/rheumatology/kei075] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
253 Sands BE. New therapies for the treatment of inflammatory bowel disease. Surg Clin North Am. 2006;86:1045-1064. [PMID: 16905423 DOI: 10.1016/j.suc.2006.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
254 Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685-698. [PMID: 21427713 DOI: 10.1038/ajg.2011.103] [Cited by in Crossref: 202] [Cited by in F6Publishing: 198] [Article Influence: 18.4] [Reference Citation Analysis]
255 Fumery M, Tilmant M, Yzet C, Brazier F, Loreau J, Turpin J, Le Mouel JP, Goeb V, Nguyen-khac E, Singh S, Dupas J, Diouf M. Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysis. Digestive and Liver Disease 2019;51:484-8. [DOI: 10.1016/j.dld.2018.12.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
256 Allez M. [Practical use of anti-TNF monoclonal antibodies in inflammatory bowel diseases]. Gastroenterol Clin Biol 2008;32:467-77. [PMID: 18448294 DOI: 10.1016/j.gcb.2008.03.002] [Reference Citation Analysis]
257 Christophorou D, Funakoshi N, Duny Y, Valats J, Bismuth M, Pineton De Chambrun G, Daures J, Blanc P. Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis. Aliment Pharmacol Ther 2015;41:603-12. [DOI: 10.1111/apt.13102] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
258 Abreu MT. DDS Perspective: My Take on Therapeutic Drug Monitoring in IBD. Dig Dis Sci 2019;64:3377-81. [PMID: 31628571 DOI: 10.1007/s10620-019-05796-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
259 Scherer K, Ballmer-weber BK, Bircher AJ. Highlights in nonhymenoptera anaphylaxis. Current Opinion in Allergy & Clinical Immunology 2008;8:348-53. [DOI: 10.1097/aci.0b013e32830638df] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
260 Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OØ, Innes A. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005;129:807-818. [PMID: 16143120 DOI: 10.1053/j.gastro.2005.06.064] [Cited by in Crossref: 419] [Cited by in F6Publishing: 369] [Article Influence: 24.6] [Reference Citation Analysis]
261 Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004;2:731-743. [PMID: 15354273 DOI: 10.1016/s1542-3565(04)00344-1] [Cited by in Crossref: 145] [Cited by in F6Publishing: 42] [Article Influence: 8.1] [Reference Citation Analysis]
262 Felley C, Michetti P. Safety of infliximab in patients suffering from inflammatory bowel disease. Digestion 2004;70:1-2. [PMID: 15297772 DOI: 10.1159/000080074] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
263 Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 2014;53:213-22. [PMID: 23946436 DOI: 10.1093/rheumatology/ket260] [Cited by in Crossref: 127] [Cited by in F6Publishing: 111] [Article Influence: 14.1] [Reference Citation Analysis]
264 Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study. World J Gastroenterol 2007; 13(16): 2328-2332 [PMID: 17511032 DOI: 10.3748/wjg.v13.i16.2328] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 60] [Article Influence: 4.1] [Reference Citation Analysis]
265 Egan LJ, Sandborn WJ. Positioning novel biologic, probiotic, and apheresis therapies for crohn’s disease and ulcerative colitis. Curr Gastroenterol Rep 2005;7:485-91. [DOI: 10.1007/s11894-005-0080-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
266 Absah I, Stephens M. Adjunctive treatment to antitumor necrosis factor in pediatric patient with refractory Crohn’s disease. Curr Opin Pediatr. 2013;Epub ahead of print. [PMID: 23995433 DOI: 10.1097/mop.0b013e328364df22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
267 Sandborn WJ. Preventing antibodies to infliximab in patients with Crohn's disease: Optimize not immunize. Gastroenterology 2003;124:1140-5. [DOI: 10.1053/gast.2003.50182] [Cited by in Crossref: 68] [Cited by in F6Publishing: 54] [Article Influence: 3.6] [Reference Citation Analysis]
268 Van Assche G, Vermeire S, Rutgeerts P. Infliximab therapy for patients with inflammatory bowel disease: 10 years on. Eur J Pharmacol 2009;623 Suppl 1:S17-25. [PMID: 19837056 DOI: 10.1016/j.ejphar.2009.10.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
269 Bultman E, de Haar C, van Liere-Baron A, Verhoog H, West RL, Kuipers EJ, Zelinkova Z, van der Woude CJ. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients. Aliment Pharmacol Ther. 2012;35:335-341. [PMID: 22191671 DOI: 10.1111/j.1365-2036.2011.04946.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 6.5] [Reference Citation Analysis]
270 Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Østergaard Thomsen O, Seidelin JB. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol. 2012;47:518-527. [PMID: 22375898 DOI: 10.3109/00365521.2012.660541] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 6.9] [Reference Citation Analysis]
271 Afzal NA, Ozzard A, Keady S, Thomson M, Murch S, Heuschkel R. Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn' disease. Dig Dis Sci 2007;52:3329-33. [PMID: 17805970 DOI: 10.1007/s10620-007-8102-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
272 Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterol. 2016;7:289-300. [PMID: 28839870 DOI: 10.1136/flgastro-2016-100685] [Cited by in Crossref: 60] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]
273 Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol 2008;159:527-36. [PMID: 18627374 DOI: 10.1111/j.1365-2133.2008.08728.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 4.6] [Reference Citation Analysis]
274 Fukunaga K, Yokoyama Y, Kamikozuru K, Yoshida K, Kikuyama R, Nagase K, Nakamura S, Takei Y, Miwa H, Matsumoto T. Selective depletion of peripheral granulocyte/monocyte enhances the efficacy of scheduled maintenance infliximab in Crohn's disease. J Clin Apher. 2010;25:226-228. [PMID: 20544712 DOI: 10.1002/jca.20242] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
275 Baert F, Drobne D, Gils A, Vande Casteele N, Hauenstein S, Singh S, Lockton S, Rutgeerts P, Vermeire S. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol. 2014;12:1474-1481.e2; quiz e91. [PMID: 24486408 DOI: 10.1016/j.cgh.2014.01.033] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 10.8] [Reference Citation Analysis]
276 Rocha C, Lago P, Fernandes S, Correia L, Portela F, Vieira AI, Patita M, Arroja B, Ministro P, Alves C, Dias CC, Magro F. Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays. Therap Adv Gastroenterol 2020;13:1756284820965790. [PMID: 33281935 DOI: 10.1177/1756284820965790] [Reference Citation Analysis]
277 Pastorelli L, Pizarro TT, Cominelli F, Vecchi M. Emerging drugs for the treatment of ulcerative colitis. Expert Opin Emerg Drugs 2009;14:505-21. [PMID: 19656075 DOI: 10.1517/14728210903146882] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
278 Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, Vande Casteele N. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015;21:182-197. [PMID: 25222660 DOI: 10.1097/mib.0000000000000202] [Cited by in Crossref: 100] [Cited by in F6Publishing: 36] [Article Influence: 14.3] [Reference Citation Analysis]
279 Bartoli F, Bruni C, Cometi L, Blagojevic J, Fiori G, Tofani L, Galluccio F, Furst DE, Matucci Cerinic M. Premedication prevents infusion reactions and improves retention rate during infliximab treatment. Clin Rheumatol 2016;35:2841-5. [DOI: 10.1007/s10067-016-3351-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
280 Saraceno R, Saggini A, Pietroleonardo L, Chimenti S. Infliximab in the treatment of plaque type psoriasis. Clin Cosmet Investig Dermatol 2009;2:27-37. [PMID: 21436966 DOI: 10.2147/ccid.s3413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
281 Barlow NL, Mohammed P, Berg JD. Serum trough infliximab and anti-infliximab antibodies in a cohort of gastroenterology and rheumatology patients' infliximab therapeutic drug monitoring. Ann Clin Biochem 2016;53:477-84. [PMID: 26290514 DOI: 10.1177/0004563215604866] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
282 Van Assche G, Vermeire S, Rutgeerts P. Focus on Mechanisms of Inflammation in Inflammatory Bowel Disease Sites of Inhibition: Current and Future Therapies. Gastroenterology Clinics of North America 2006;35:743-56. [DOI: 10.1016/j.gtc.2006.09.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
283 Molander P, Färkkilä M, Kemppainen H, Blomster T, Jussila A, Mustonen H, Sipponen T. Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents. Scandinavian Journal of Gastroenterology 2017;52:284-90. [DOI: 10.1080/00365521.2016.1250942] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
284 Kavanaugh AF, Mayer LF, Cush JJ, Hanauer SB. Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease. Am J Med 2011;124:e1-18. [PMID: 21531240 DOI: 10.1016/j.amjmed.2011.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
285 Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, Bachelez H, Morel P, Lebbé C. Infliximab for severe hidradenitis suppurativa: Transient clinical efficacy in 7 consecutive patients. Journal of the American Academy of Dermatology 2007;56:624-8. [DOI: 10.1016/j.jaad.2006.07.027] [Cited by in Crossref: 95] [Cited by in F6Publishing: 75] [Article Influence: 6.3] [Reference Citation Analysis]
286 Falsey A, Jo D, Sirak H, Moya D, Leibowitz IH, Yang J, Hourigan SK, May E. Corticosteroids Can Be Used to Decrease Antidrug Antibodies in Pediatric Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab182. [PMID: 34319399 DOI: 10.1093/ibd/izab182] [Reference Citation Analysis]
287 Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis. 2007;13:1024-1030. [PMID: 17480018 DOI: 10.1002/ibd.20169] [Cited by in Crossref: 169] [Cited by in F6Publishing: 145] [Article Influence: 11.3] [Reference Citation Analysis]
288 Sandborn WJ. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep 2003;5:501-5. [DOI: 10.1007/s11894-003-0040-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
289 Raho G, Vena GA, Bizzoca A, Cassano N, Garofalo E, Congedo M, Gennarini G. Influence of infliximab on keratinocyte apoptosis in psoriasis patients. Immunopharmacology and Immunotoxicology 2010;33:227-31. [DOI: 10.3109/08923973.2010.487068] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
290 Pariente B, Pineton de Chambrun G, Krzysiek R, Desroches M, Louis G, De Cassan C, Baudry C, Gornet JM, Desreumaux P, Emilie D. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:1199-1206. [PMID: 22127789 DOI: 10.1002/ibd.21839] [Cited by in Crossref: 86] [Cited by in F6Publishing: 82] [Article Influence: 7.8] [Reference Citation Analysis]
291 Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010;32:1228-1239. [PMID: 20955442 DOI: 10.1111/j.1365-2036.2010.04466.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 85] [Article Influence: 8.2] [Reference Citation Analysis]
292 Bewtra M, Lichtenstein GR. Infliximab use in Crohn’s disease. Expert Opinion on Biological Therapy 2005;5:589-99. [DOI: 10.1517/14712598.5.4.589] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
293 Oussalah A, Babouri A, Chevaux JB, Stancu L, Trouilloud I, Bensenane M, Boucekkine T, Bigard MA, Peyrin-Biroulet L. Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Aliment Pharmacol Ther. 2009;29:416-423. [PMID: 19035976 DOI: 10.1111/j.1365-2036.2008.03902.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
294 Moss AC, Fernandez-Becker N, Jo Kim K, Cury D, Cheifetz AS. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. Aliment Pharmacol Ther 2008;28:221-7. [PMID: 18485127 DOI: 10.1111/j.1365-2036.2008.03734.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
295 Yarur AJ, Rubin DT. Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis 2015;21:1709-18. [PMID: 25901974 DOI: 10.1097/MIB.0000000000000380] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
296 Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004;53:1366-73. [PMID: 15306602 DOI: 10.1136/gut.2003.025452] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
297 Sorrentino D, Nguyen V, Henderson C, Bankole A. Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link. Inflamm Bowel Dis. 2016;22:2527-2537. [PMID: 27575494 DOI: 10.1097/mib.0000000000000867] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
298 Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn’s disease. Scand J Gastroenterol. 2011;46:310-318. [PMID: 21087119 DOI: 10.3109/00365521.2010.536254] [Cited by in Crossref: 139] [Cited by in F6Publishing: 134] [Article Influence: 11.6] [Reference Citation Analysis]
299 Etchevers MJ, Ordás I, Ricart E. Optimizing the Use of Tumour Necrosis Factor Inhibitors in Crohnʼs Disease: A Practical Approach. Drugs 2010;70:109-20. [DOI: 10.2165/11533700-000000000-00000] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
300 Corstjens PL, Fidder HH, Wiesmeijer KC, de Dood CJ, Rispens T, Wolbink GJ, Hommes DW, Tanke HJ. A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study. Anal Bioanal Chem. 2013;405:7367-7375. [PMID: 23836086 DOI: 10.1007/s00216-013-7154-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
301 Solem CA, Loftus EV Jr. Management of refractory inflammatory bowel disease. Gastroenterol Clin North Am 2004;33:319-34, x. [PMID: 15177541 DOI: 10.1016/j.gtc.2004.02.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
302 Zwiers A, Bouma G. Recent advances in the etiology and treatment of inflammatory bowel disease. Expert Rev Clin Immunol 2006;2:245-56. [PMID: 20477075 DOI: 10.1586/1744666X.2.2.245] [Reference Citation Analysis]
303 Caviglia R, Boskoski I, Cicala M. Maintenance treatment with infliximab for the management of Crohn's disease in adults. Biologics 2009;3:39-49. [PMID: 19707394 DOI: 10.2147/btt.2009.2763] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
304 Osterman MT, Lichtenstein GR. Current and Future Anti-TNF Therapy for Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2007;10:195-207. [PMID: 17547858 DOI: 10.1007/s11938-007-0013-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
305 Van Assche G, Vermeire S, Rutgeerts P. Optimizing treatment of inflammatory bowel diseases with biologic agents. Curr Gastroenterol Rep 2008;10:591-6. [DOI: 10.1007/s11894-008-0107-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
306 Eser A, Primas C, Reinisch W. Drug monitoring of biologics in inflammatory bowel disease. Curr Opin Gastroenterol. 2013;29:391-396. [PMID: 23703367 DOI: 10.1097/MOG.0b013e328361f7f6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
307 Trivedi HD, Shannahan SE, Morrow M, Peppercorn MA. Using Adalimumab to Treat Autoimmune Enteropathy. ACG Case Rep J 2019;6:e00265. [PMID: 32309471 DOI: 10.14309/crj.0000000000000265] [Reference Citation Analysis]
308 Kansen HM, van Rheenen PF, Houwen RHJ, Tjon A Ten W, Damen GM, Kindermann A, Escher JC, Wolters VM; Kids with Crohnʼs, Colitis (KiCC) Working Group for Collaborative Paediatric IBD Research in the Netherlands. Less Anti-infliximab Antibody Formation in Paediatric Crohn Patients on Concomitant Immunomodulators. J Pediatr Gastroenterol Nutr 2017;65:425-9. [PMID: 28945207 DOI: 10.1097/MPG.0000000000001551] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
309 Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol. 2011;7:55-63. [PMID: 21162650 DOI: 10.1586/eci.10.90] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 6.9] [Reference Citation Analysis]
310 Freeman K, Taylor-Phillips S, Connock M, Court R, Tsertsvadze A, Shyangdan D, Auguste P, Mistry H, Arasaradnam R, Sutcliffe P, Clarke A. Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn's disease: a systematic review and meta-analysis. BMJ Open 2017;7:e014581. [PMID: 28674134 DOI: 10.1136/bmjopen-2016-014581] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
311 Alessandri C, Scrivo R, Spinelli FR, Ceccarelli F, Magrini L, Priori R, Valesini G. Autoantibody production in anti-TNF-alpha-treated patients. Ann N Y Acad Sci 2007;1110:319-29. [PMID: 17911447 DOI: 10.1196/annals.1423.034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
312 Schröder O, Blumenstein I, Stein J. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. Eur J Gastroenterol Hepatol 2006;18:11-6. [PMID: 16357613 DOI: 10.1097/00042737-200601000-00003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
313 Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987. [PMID: 16530532 DOI: 10.1053/j.gastro.2006.01.048] [Cited by in Crossref: 328] [Cited by in F6Publishing: 303] [Article Influence: 20.5] [Reference Citation Analysis]
314 Meier J, Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol 2011; 17(27): 3204-3212 [PMID: 21912469 DOI: 10.3748/wjg.v17.i27.3204] [Cited by in F6Publishing: 34] [Reference Citation Analysis]
315 Donovan M, Lunney K, Carter-Pokras O, Cross RK. Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists. Dig Dis Sci 2007;52:1798-805. [PMID: 17417731 DOI: 10.1007/s10620-006-9269-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
316 Zhang QW, Shen J, Zheng Q, Ran ZH. Loss of response to scheduled infliximab therapy for Crohn's disease in adults: A systematic review and meta‐analysis. J Dig Dis 2019;20:65-72. [DOI: 10.1111/1751-2980.12698] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
317 Loftus EV. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time. Am J Gastroenterol 2005;100:1435-8. [PMID: 15984960 DOI: 10.1111/j.1572-0241.2005.50622_2.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
318 Sandborn WJ, Hanauer S, Loftus EV, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol. 2004;99:1984-1989. [PMID: 15447761 DOI: 10.1111/j.1572-0241.2004.40462.x] [Cited by in Crossref: 181] [Cited by in F6Publishing: 173] [Article Influence: 10.1] [Reference Citation Analysis]
319 Ben-horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease: Review: loss of response to anti-TNF in Crohn’s disease. Alimentary Pharmacology & Therapeutics 2011;33:987-95. [DOI: 10.1111/j.1365-2036.2011.04612.x] [Cited by in Crossref: 328] [Cited by in F6Publishing: 304] [Article Influence: 29.8] [Reference Citation Analysis]
320 Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis. 2009;15:1264-1275. [PMID: 19235918 DOI: 10.1002/ibd.20899] [Cited by in Crossref: 96] [Cited by in F6Publishing: 89] [Article Influence: 7.4] [Reference Citation Analysis]
321 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
322 Roda G, Jharap B, Neeraj N, Colombel JF. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol. 2016;7:e135. [PMID: 26741065 DOI: 10.1038/ctg.2015.63] [Cited by in Crossref: 236] [Cited by in F6Publishing: 216] [Article Influence: 39.3] [Reference Citation Analysis]
323 Magdelaine-beuzelin C, Vermeire S, Goodall M, Baert F, Noman M, Assche GV, Ohresser M, Degenne D, Dugoujon J, Jefferis R, Rutgeerts P, Lefranc M, Watier H. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenetics and Genomics 2009;19:383-7. [DOI: 10.1097/fpc.0b013e32832a06bf] [Cited by in Crossref: 63] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
324 Crommelin HA, Vorselaars AD, van Moorsel CH, Korenromp IH, Deneer VH, Grutters JC. Anti-TNF therapeutics for the treatment of sarcoidosis. Immunotherapy 2014;6:1127-43. [PMID: 25428650 DOI: 10.2217/imt.14.65] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
325 Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65. [PMID: 17241859 DOI: 10.1053/j.gastro.2006.11.041] [Cited by in Crossref: 1456] [Cited by in F6Publishing: 1258] [Article Influence: 91.0] [Reference Citation Analysis]
326 Ducharme J, Pelletier C, Zacharias R. Premedications for infliximab infusions do not impact the risk of acute adverse drug reactions. Frontline Gastroenterol 2011;2:249-54. [PMID: 28839619 DOI: 10.1136/flgastro-2011-100030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
327 Vande Casteele N, Khanna R. Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis. Pharm Res 2017;34:1556-63. [PMID: 28374338 DOI: 10.1007/s11095-017-2150-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
328 Chaparro M, Guerra I, Muñoz-Linares P, Gisbert JP. Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012;35:971-86. [PMID: 22443153 DOI: 10.1111/j.1365-2036.2012.05057.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
329 Van Assche G, Vermeire S, Rutgeerts P. Safety issues with biological therapies for inflammatory bowel disease. Curr Opin Gastroenterol 2006;22:370-6. [PMID: 16760752 DOI: 10.1097/01.mog.0000231810.87901.e8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
330 Ferrante M, D’haens G, Rutgeerts P, Vermeire S, Van Assche G. Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and crohn’s disease). Curr Gastroenterol Rep 2009;11:504-8. [DOI: 10.1007/s11894-009-0076-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
331 Ha C, Mathur J, Kornbluth A. Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2015;9:497-505. [PMID: 25600263 DOI: 10.1586/17474124.2015.983079] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
332 de Bie CI, Escher JC, de Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:985-1002. [PMID: 21936033 DOI: 10.1002/ibd.21871] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
333 Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-33; quiz 591. [PMID: 16472588 DOI: 10.1053/j.gastro.2005.11.030] [Cited by in Crossref: 1055] [Cited by in F6Publishing: 961] [Article Influence: 65.9] [Reference Citation Analysis]
334 Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Therap Adv Gastroenterol 2013;6:269-93. [PMID: 23814608 DOI: 10.1177/1756283X13479826] [Cited by in Crossref: 51] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
335 Sánchez AR, Rogers RS 3rd, Sheridan PJ. Oral ulcerations are associated with the loss of response to infliximab in Crohn's disease. J Oral Pathol Med 2005;34:53-5. [PMID: 15610407 DOI: 10.1111/j.1600-0714.2004.00273.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
336 Choquette D, Faraawi R, Chow A, Rodrigues J, Bensen WJ, Nantel F. Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry. J Rheumatol 2015;42:1105-11. [DOI: 10.3899/jrheum.140538] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
337 Dulai PS, Siegel CA, Peyrin-Biroulet L. Anti-tumor necrosis factor-α monotherapy versus combination therapy with an immunomodulator in IBD. Gastroenterol Clin North Am 2014;43:441-56. [PMID: 25110252 DOI: 10.1016/j.gtc.2014.05.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
338 Wasan SK, Kane SV. Adalimumab for the treatment of inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2011;5:679-84. [PMID: 22017695 DOI: 10.1586/egh.11.81] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
339 Finckh A, Simard JF, Gabay C, Guerne PA. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis. 2006;65:746-752. [PMID: 16339288 DOI: 10.1136/ard.2005.045062] [Cited by in Crossref: 114] [Cited by in F6Publishing: 101] [Article Influence: 6.7] [Reference Citation Analysis]
340 Winter TA, Sandborn WJ, de Villiers WJ, Schreiber S. Treatment of Crohn’s disease with certolizumab pegol. Expert Review of Clinical Immunology 2014;3:683-94. [DOI: 10.1586/1744666x.3.5.683] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
341 Shen C, Van Assche G, Rutgeerts P, Ceuppens JL. Caspase activation and apoptosis induction by adalimumab: Demonstration in vitro and in vivo in a chimeric mouse model: . Inflammatory Bowel Diseases 2006;12:22-8. [DOI: 10.1097/01.mib.0000194185.69800.07] [Cited by in Crossref: 43] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
342 Lavagna A, Bergallo M, Daperno M, Sostegni R, Costa C, Leto R, Crocellà L, Molinaro G, Rocca R, Cavallo R. Infliximab and the risk of latent viruses reactivation in active Crohn’s disease. Inflamm Bowel Dis. 2007;13:896-902. [PMID: 17345605 DOI: 10.1002/ibd.20131] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 4.9] [Reference Citation Analysis]
343 O'Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:1-6. [PMID: 24280879 DOI: 10.1097/01.mib.0000436951.80898.6d] [Cited by in Crossref: 98] [Cited by in F6Publishing: 35] [Article Influence: 12.3] [Reference Citation Analysis]
344 Gonvers J, Juillerat P, Mottet C, Pittet V, Felley C, Vader J, Michetti P, Froehlich F. Maintenance of Medically Induced Remission of Crohn’s Disease. Digestion 2008;76:116-29. [DOI: 10.1159/000111026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
345 Khanna R, Chande N, Vermeire S, Sandborn WJ, Parker CE, Feagan BG. The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews. Inflammatory Bowel Diseases 2016;22:1737-43. [DOI: 10.1097/mib.0000000000000808] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
346 Vande Casteele N, Gils A. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice. J Clin Pharmacol. 2015;55 Suppl 3:S39-S50. [PMID: 25707962 DOI: 10.1002/jcph.374] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 9.1] [Reference Citation Analysis]
347 Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther. 2004;20:1337-1346. [PMID: 15606396 DOI: 10.1111/j.1365-2036.2004.02285.x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 81] [Article Influence: 5.6] [Reference Citation Analysis]
348 Thomas SS, Borazan N, Barroso N, Duan L, Taroumian S, Kretzmann B, Bardales R, Elashoff D, Vangala S, Furst DE. Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis. BioDrugs 2015;29:241-58. [DOI: 10.1007/s40259-015-0134-5] [Cited by in Crossref: 96] [Cited by in F6Publishing: 89] [Article Influence: 13.7] [Reference Citation Analysis]
349 Weir N, Athwal D, Brown D, Foulkes R, Kollias G, Nesbitt A, Popplewell A, Spitali M, Stephens S. A new generation of high-affinity humanized PEGylated Fab� fragment anti-tumor necrosis factor-? monoclonal antibodies. Therapy 2006;3:535-45. [DOI: 10.1586/14750708.3.4.535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
350 Allez M, Vermeire S, Mozziconacci N, Michetti P, Laharie D, Louis E, Bigard MA, Hébuterne X, Treton X, Kohn A. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010;31:92-101. [PMID: 19709098 DOI: 10.1111/j.1365-2036.2009.04130.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 6.7] [Reference Citation Analysis]
351 Prado MS, Bendtzen K, Andrade LEC. Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events. Expert Opinion on Drug Metabolism & Toxicology 2017;13:985-95. [DOI: 10.1080/17425255.2017.1360280] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
352 Allez M, Karmiris K, Louis E, Van Assche G, Ben-Horin S, Klein A, Van der Woude J, Baert F, Eliakim R, Katsanos K. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010;4:355-366. [PMID: 21122530 DOI: 10.1016/j.crohns.2010.04.004] [Cited by in Crossref: 210] [Cited by in F6Publishing: 191] [Article Influence: 17.5] [Reference Citation Analysis]
353 Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Aliment Pharmacol Ther. 2006;23:451-463. [PMID: 16441465 DOI: 10.1111/j.1365-2036.2006.02786.x] [Cited by in Crossref: 168] [Cited by in F6Publishing: 162] [Article Influence: 10.5] [Reference Citation Analysis]
354 Jossen J, Dubinsky M. Therapeutic drug monitoring in inflammatory bowel disease. Curr Opin Pediatr 2016;28:620-5. [PMID: 27583410 DOI: 10.1097/MOP.0000000000000393] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
355 Nuñez F P, Quera R, Simian D, Flores L, Figueroa C, Ibañez P, Kronberg U, Lubascher J, Pizarro G. Infliximab in inflammatory bowel disease. Is premedication necessary? Gastroenterol Hepatol 2021;44:321-9. [PMID: 33386199 DOI: 10.1016/j.gastrohep.2020.07.018] [Reference Citation Analysis]